Moody's Says Alkermes (ALKS) FORWARD-5 Data is Credit-Positive Development

October 21, 2016 2:31 PM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Moody's Investors Service commented that the positive clinical data of Alkermes' (Nasdaq: ALKS) experimental depression drug ALKS-5461 is credit positive. There is no effect on Alkermes' ratings including the Ba3 Corporate Family Rating, or the negative rating outlook.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Credit Ratings

Related Entities

Moody's Investors Service

Add Your Comment